Phase 2 N=10 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Recurrent Prostate Carcinoma
Primary: Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution — 12.4 SUVmax
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Phase 2 N=62 A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Overall Response — 8.3 percentage of participants
Phase 2 N=35 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Thymoma · Thymus Cancer · Thymic Carcinoma
Primary: Overall Response Rate (ORR) — 0; 6; 6 Participants
Phase 2 N=95 Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Breast Cancer
Primary: Number of Patients Who Completed All Planned Therapy — 45 participants
Phase 2 N=20 Mechanisms of Desensitization During Peanut Oral Immunotherapy
Food Hypersensitivity
Primary: Percentage of Subjects Who Develop Desensitization — 81.25 percentage of participants
Phase 2 N=75 DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: The Number of Subjects With HPA Axis Suppression — 0; 5; 5 Participants
Phase 2 N=6 Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
Diabetes · Metabolic Syndrome · Insulin Resistance
Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale
Phase 2 N=44 Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: To Evaluate the Best Overall Response Rate (ORR) — 1; 8; 9; 3 Participants
Phase 2 N=287 Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
Osteoporosis Postmenopausal
Primary: Percent Change From Baseline to Week 52 in Lumbar Spine Bone Mineral Density (BMD) at Lumbar Vertebrae 1 to 4 (L1-L4) — 0.55; 4.09; 5.67; 5.94 percent change — p=<0.001
Phase 2 N=62 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
COPD
Primary: Change From Baseline to Day 7 in Trough FEV1 (Forced Expiratory Volume in 1 Second) — 91.2; 92.8; 113.1; 151.9 FEV1 (mL)
Phase 2 N=34 An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs — 8; 6; 9; 9 Participants
Phase 2 N=465 Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response After First Course — 67.1 percentage of participants
Phase 2 N=25 Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Breast Cancer
Primary: Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months — -3.0 percentage of positive cells — p=<0.001
Phase 2 N=129 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days